Heiz-Valle C, de Maistre E, Commun N, Heck M, Lecompte T, Hoffman M
Service Pharmacie, Hôpital Central, Nancy.
Therapie. 2002 Jan-Feb;57(1):34-8.
Since March 1999, desirudin (REVASC), a recombinant hirudin, has been used in Nancy to treat patients who undergo total hip or knee replacement with a high risk of thromboembolic complications. We carried out a retrospective study using clinical data on the first 15 consecutive patients treated with desirudin to find out prescription motivations, type of shift (indirect anticoagulants or low-molecular-weight-heparin) and evolution. They all had a high risk of deep vein thrombosis (thrombophily, obesity, history of thromboembolic events). Some of this patients would have been excluded of the studies which permitted desirudin to be approved. In this study, we found no thromboembolic complications. The only striking facts are one bleeding complication (after difficult surgery) and one pulmonary embolism (2 months later).
自1999年3月以来，重组水蛭素去氨加压素（REVASC）已在南锡用于治疗全髋关节或膝关节置换术后有高血栓栓塞并发症风险的患者。我们利用连续接受去氨加压素治疗的前15例患者的临床数据进行了一项回顾性研究，以了解处方动机、转换类型（间接抗凝剂或低分子肝素）及病情发展。所有患者均有深静脉血栓形成的高风险（血栓形成倾向、肥胖、有血栓栓塞事件史）。部分此类患者会被允许去氨加压素获批的研究排除在外。在本研究中，我们未发现血栓栓塞并发症。唯一显著的情况是1例出血并发症（手术困难后）和1例肺栓塞（2个月后）。
